Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: A case series and literature review

Supportive Care in Cancer

Volumn 21, Issue 10, 2013, Pages 2679-2686

  Poi, Ming J ^a   Berger, Michael ^a   Lustberg, Maryam ^b   Layman, Rachel ^b   Shapiro, Charles L ^b   Ramaswamy, Bhuvaneswari ^b   Mrozek, Ewa ^b   Olson, Erin ^b   Wesolowski, Robert ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Chemotherapy toxicity; Hand foot syndrome; Taxane

Indexed keywords

ALUMINUM ACETATE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CEFALEXIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EMOLLIENT AGENT; FAMOTIDINE; GABAPENTIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; IBUPROFEN; LEVOFLOXACIN; MORPHINE; OXYCODONE; PACLITAXEL; PARACETAMOL; PETROLATUM; PYRIDOXINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRAMADOL; TRIAMCINOLONE; VANCOMYCIN;

ADULT; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BLISTER; BLURRED VISION; BREAST CANCER; BREAST CARCINOMA; BURNING SENSATION; CANCER ADJUVANT THERAPY; CANCER PATIENT; CASE STUDY; CLINICAL ARTICLE; COUGHING; CRYOTHERAPY; CYTOMEGALOVIRUS INFECTION; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; EYE BURNING; FATIGUE; FEMALE; FEVER; FOOT PAIN; HAND FOOT SYNDROME; HAND PAIN; HUMAN; INCIDENCE; INTRADUCTAL CARCINOMA; JAW PAIN; LACRIMATION; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NOSE DISCHARGE; NOSE DISEASE; PAIN; PARESTHESIA; PERIORBITAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; PYODERMA GANGRENOSUM; RASH; SIDE EFFECT; SKIN REDNESS; SKIN TINGLING; SKIN TOXICITY; SWELLING; URINALYSIS; URINARY FREQUENCY; URINARY TRACT INFECTION; VIREMIA; VOMITING; WALKING DIFFICULTY; WEAKNESS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; MIDDLE AGED; PACLITAXEL; SKIN DISEASES; SURVIVAL RATE; TAXOIDS;

EID: 84884287826     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1842-3     Document Type: Article

References (45)

1. National Comprehensive Cancer Network (2011) NCCN clinical practice guidelines in oncology. Breast Cancer. 2011; v2: BINV-K. Available at: www.nccn.org/. Accessed 15 Dec 2011
2. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2:1431-1439
3. Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671
4. Harvey V, Mouridsen H, Semiglazov V et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 4:4963-4970
5. Tabernero J, Climent MA, Lluch A et al (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365
6. Chan S, Friedrichs K, Noel D, 303 Study Group et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
7. Nabholtz JM, Senn HJ, Bezwoda WR et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 7:1413-1424
8. Swain SM, Jeong JH, Geyer CE Jr et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-2065
9. Sanofi-Aventis Medical Information Services (2011) Information on file. Accessed 14 Sept 2011
10. Burstein HJ, Manola J, Younger J et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219
11. Ford HE, Yap YS, Miles DW et al (2006) A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol 58:809-815
12. Rivera E, Mejia JA, Arun BK et al (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455-1461
13. Stemmler HJ, Harbeck N, Gröll de Rivera I et al (2010) Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. Oncology 79:197-203
14. Taxotere (docetaxel) Injection [prescribing information] (2010) Sanofi-Aventis U.S. LLC, Bridgewater
15. Hui YF, Giles FJ, Cortes JE (2002) Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome - recall following different chemotherapy agents. Invest New Drugs 20:49-53
16. Chew L, Chuen VS (2009) Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 15:29-34
17. Nagore E, Insa A, Sanmartin O (2000) Antineoplastic therapy-induced palmar-plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1:225-234
18. Webster-Gandy JD, How C, Harrold K (2007) Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11:238-246
19. Childress J, Lokich J (2003) Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 26:435-436
20. Battafarano DF, Zimmerman GC, Older SA et al (1995) Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 76:110-115
21. Fitzpatrick JE (1993) The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 20:1-14
22. Jacobi U, Waibler E, Schulze P et al (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 16:1210-1211
23. Cox GJ, Robertson DB (1986) Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol 122:1413-1414
24. Bardia A, Loprinzi CL, Goetz MP (2006) Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. J Clin Oncol 24:e18-e19
25. Marre F, Sanderink GJ, de Sousa G et al (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
26. 2 blockers: a multi-institution survey. Breast Cancer Res Treat 130:627-634
27. Di Leo A, Crown J, Nogaret JM et al (2000) A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 11:169-175
28. Miller KD, McCaskill-Stevens W, Sisk J et al (1999) Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037
29. Schwartz J, Domchek SM, Hwang WT et al (2005) Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/ cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 16:247-252
30. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685
31. Cooper BW, Radivoyevitch T, Overmoyer BA et al (2006) Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 97:311-318
32. Lambert-Falls R, Modugno S (2007) Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study. Clin Breast Cancer 7:697-704
33. Puhalla S, Mrozek E, Young D et al (2008) Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol 26:1691-1697
34. Antolín S, Mel R, Ramos M et al (2011) A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. Clin Transl Oncol 13:686-691
35. Yoshimoto N, Yamashita T, Fujita T et al (2010) Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer 17:298-302
36. Fabian CJ, Molina R, Slavik M et al (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57-63
37. Kang YK, Lee SS, Yoon DH et al (2010) Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 28:3824-3829
38. Scotte F, Tourani J-M, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23:4424-4429
39. Scotte F, Banu E, Medioni J et al (2008) Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 112:1625-1631
40. Grevelman EG, Breed WP (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16:352-358
41. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV et al (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51:497-504
42. Lopez AM, Wallace L, Dorr RT et al (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 44:303-306
43. Kara IO, Sahin B, Erkisi M (2006) Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 15:414-424
44. Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12:131-141
45. von Moos R, Thuerlimann BJ, Aapro M et al (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44:781-790